Lupus Erythematosus (SLE)

Categories: Blood diseases, Bone diseases, Genetic diseases, Immune diseases, Nephrological diseases, Rare diseases, Skin diseases

Aliases & Classifications for Lupus Erythematosus

MalaCards integrated aliases for Lupus Erythematosus:

Name: Lupus Erythematosus 12 74 52 54 15 71 32
Lupus 12 52 15
Subacute Cutaneous Lupus 52 71
Disseminated Lupus Erythematosus 52
Lupus Erythematosus, Systemic 71
Systemic Lupus Erythematosus 52
Lupus Erythematosus, Discoid 71
Lupus Vulgaris 71
Discoid Lupus 52
Sle 52


External Ids:

Disease Ontology 12 DOID:8857
ICD9CM 34 695.4
NCIt 49 C27153
ICD10 32 L93 L93.0
UMLS 71 C0024131 C0024138 C0024141 more

Summaries for Lupus Erythematosus

NIH Rare Diseases : 52 Lupus is an autoimmune disease that can affect almost every organ in the body. Symptoms of lupus can range from very mild to life-threatening. There are three main types of lupus; systemic lupus erythematosus , discoid lupus , and drug-induced lupus. Symptoms may include pain or swelling in joints, muscle pain, fever, red rashes, most often on the face (also called the "butterfly rash"), hair loss, chest pain, sensitivity to the sun, swelling in legs or around the eyes, and feeling tired. Genetics is thought to play a role in the development of lupus along with other lifestyle and environmental factors . Studies suggest that a number of different genes may be involved in determining a person's likelihood of developing the disease, which tissues and organs are affected, and the severity of disease. Lupus is more common in young women. The treatment of lupus depends on the severity of the condition and what parts of the body are affected. Treatment may include acetaminophen , ibuprofen , antimalarial drugs, anti-inflammatory steroids, immunosuppressive drugs, and other such as BLyS-specific inhibitors (Belimumab ).

MalaCards based summary : Lupus Erythematosus, also known as lupus, is related to systemic lupus erythematosus 16 and subacute cutaneous lupus erythematosus, and has symptoms including rashes, seizures and pruritus. An important gene associated with Lupus Erythematosus is TLR5 (Toll Like Receptor 5), and among its related pathways/superpathways are Innate Immune System and Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3. The drugs Mycophenolic acid and chloroquine have been mentioned in the context of this disorder. Affiliated tissues include t cells, b cells and skin, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 An autoimmune hypersensitivity disease that is characterized by a constellation of findings that include elevated antibodies to nuclear antigens, antiphospholipids, low complement levels, ulcers, non-scarring alopecia, renal or neurologic damage, and low white blood cell and platelet counts, has symptom rashes, fatigue, arthritis, hair loss, seizures, and symptoms related to affected organs, and has material basis in autoimmune disorder.

Wikipedia : 74 Lupus erythematosus is a collection of autoimmune diseases in which the human immune system becomes... more...

Related Diseases for Lupus Erythematosus

Diseases in the Lupus Erythematosus family:

Systemic Lupus Erythematosus Systemic Lupus Erythematosus 15
Systemic Lupus Erythematosus 1 Systemic Lupus Erythematosus 2
Systemic Lupus Erythematosus 3 Systemic Lupus Erythematosus 4
Systemic Lupus Erythematosus 5 Systemic Lupus Erythematosus 6
Systemic Lupus Erythematosus 7 Systemic Lupus Erythematosus 8
Systemic Lupus Erythematosus 9 Systemic Lupus Erythematosus 10
Systemic Lupus Erythematosus 11 Systemic Lupus Erythematosus 12
Systemic Lupus Erythematosus 13 Systemic Lupus Erythematosus 14
Systemic Lupus Erythematosus 16

Diseases related to Lupus Erythematosus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2321)
# Related Disease Score Top Affiliating Genes
1 systemic lupus erythematosus 16 35.5 DNASE1L3 DNASE1 C4A C1QA
2 subacute cutaneous lupus erythematosus 35.4 TRIM21 C1QA
3 neonatal lupus erythematosus 35.4 TRIM21 C4A
4 pediatric systemic lupus erythematosus 35.0 STAT4 C4B C4A C1QA
5 systemic lupus erythematosus 34.9 TRIM21 TLR5 STAT4 SSB SNRPB PTPN22
6 vitiligo-associated multiple autoimmune disease susceptibility 1 34.5 PTPN22 PDCD1 CTLA4 C4B
7 chilblain lupus 1 34.0 IRF5 DNASE1L3
8 c1q deficiency 33.9 C1QC C1QB C1QA
9 aicardi-goutieres syndrome 33.6 TLR5 IRF5 DNASE1L3
10 systemic scleroderma 33.6 TRIM21 STAT4 SSB IRF5
11 autoimmune disease 32.8 TRIM21 STAT4 PTPN22 PDCD1 IRF5 FCGR3A
12 exanthem 32.7 TRIM21 PDCD1 CTLA4
13 glomerulonephritis 32.6 C4B C4A C1QC C1QB C1QA
14 thrombocytopenia 32.5 TLR5 PDCD1 FCGR3A FCGR2B CTLA4
15 systemic autoimmune disease 32.4 FCGR3A FCGR2B
16 rheumatoid arthritis 32.3 STAT4 PTPN22 PDCD1 IRF5 FCGR3A FCGR2B
17 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 32.2 PTPN22 CTLA4
18 collagen disease 32.0 TRIM21 STAT4 SSB IRF5
19 heart block, congenital 31.8 TRIM21 SSB
20 primary biliary cirrhosis 31.8 TLR5 STAT4 PDCD1 IRF5 CTLA4
21 celiac disease 1 31.6 TLR5 STAT4 PTPN22 CTLA4
22 inflammatory bowel disease 31.5 TLR5 STAT4 PTPN22 IRF5 FCGR3A CTLA4
23 mononeuritis multiplex 31.4 TRIM21 SSB
24 diabetes mellitus, insulin-dependent 31.2 TLR5 PTPN22 PDCD1 CTLA4 C4A
25 parotitis 31.1 TRIM21 SSB
26 second-degree atrioventricular block 30.9 TRIM21 SSB
27 limited scleroderma 30.8 TRIM21 SSB IRF5 BANK1
28 xerophthalmia 30.8 TRIM21 SSB
29 behcet syndrome 30.8 TLR5 STAT4 PTPN22 CTLA4 C4A
30 polyclonal hypergammaglobulinemia 30.7 TRIM21 SSB
31 multifocal motor neuropathy 30.6 PTPN22 FCGR2B BANK1
32 complement component 3 deficiency 30.6 C4B C4A
33 complement component 5 deficiency 30.6 C4B C4A C1QA
34 parotid disease 30.5 TRIM21 SSB
35 bone inflammation disease 30.5 TLR5 PTPN22 CTLA4
36 third-degree atrioventricular block 30.2 TRIM21 SSB
37 oligoarticular juvenile idiopathic arthritis 30.0 STAT4 PTPN22
38 cutaneous lupus erythematosus 13.0
39 lupus erythematosus tumidus 13.0
40 discoid lupus erythematosus 13.0
41 drug-induced lupus erythematosus 12.9
42 lupus erythematosus panniculitis 12.9
43 systemic lupus erythematosus 1 12.9
44 systemic lupus erythematosus 2 12.8
45 systemic lupus erythematosus 10 12.8
46 systemic lupus erythematosus 9 12.8
47 systemic lupus erythematosus 6 12.8
48 systemic lupus erythematosus 11 12.8
49 chronic cutaneous lupus erythematosus 12.6
50 systemic lupus erythematosus with hemolytic anemia 1 12.6

Graphical network of the top 20 diseases related to Lupus Erythematosus:

Diseases related to Lupus Erythematosus

Symptoms & Phenotypes for Lupus Erythematosus


  • rashes

UMLS symptoms related to Lupus Erythematosus:

seizures, pruritus, exanthema, heliotrope rash, lupus-like rash

GenomeRNAi Phenotypes related to Lupus Erythematosus according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00240-S-1 10.1 C1QA TRIM21
2 Decreased viability GR00381-A-1 10.1 C1QA PDCD1 SNRPB
3 Decreased viability GR00381-A-2 10.1 C1QA
4 Decreased viability GR00381-A-3 10.1 C1QA PDCD1
5 Decreased viability GR00402-S-2 10.1 BANK1 C1QA C1QB C1QC C4A C4B
6 no effect GR00402-S-1 9.62 BANK1 C1QA C1QB C1QC C4A C4B

MGI Mouse Phenotypes related to Lupus Erythematosus:

# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.07 BANK1 C4B CR2 CTLA4 DNASE1 FCGR2B
2 homeostasis/metabolism MP:0005376 9.93 C1QA C4B CR2 CTLA4 DNASE1 FCGR2B
3 immune system MP:0005387 9.8 BANK1 C1QA C4B CR2 CTLA4 DNASE1
4 renal/urinary system MP:0005367 9.28 C1QA C4B CR2 DNASE1 FCGR2B PDCD1

Drugs & Therapeutics for Lupus Erythematosus

Drugs for Lupus Erythematosus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 484)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Mycophenolic acid Approved Phase 4 24280-93-1 446541
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
Lenalidomide Approved Phase 4 191732-72-6 216326
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
Vincristine Approved, Investigational Phase 4 2068-78-2, 57-22-7 5978
Clobetasol Approved, Experimental, Investigational Phase 4 25122-46-7, 25122-41-2 32798 5311051
Linaclotide Approved Phase 4 851199-59-2 65351
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
tannic acid Approved Phase 4 1401-55-4
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
Sulfamethoxazole Approved Phase 4 723-46-6 5329
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
Lifitegrast Approved Phase 4 1025967-78-5
Artesunate Approved, Investigational Phase 4 88495-63-0 6917864 5464098
Dalteparin Approved Phase 4 9005-49-6
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
Metformin Approved Phase 4 657-24-9 14219 4091
Leflunomide Approved, Investigational Phase 4 75706-12-6 3899
Adenosine Approved, Investigational Phase 4 58-61-7 60961
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
Simvastatin Approved Phase 4 79902-63-9 54454
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
30 Interferon-alpha Phase 4
31 Antihypertensive Agents Phase 4
32 Angiotensin Receptor Antagonists Phase 4
33 Angiotensin II Type 1 Receptor Blockers Phase 4
34 Gastrointestinal Agents Phase 4
35 Dermatologic Agents Phase 4
36 Anti-Asthmatic Agents Phase 4
37 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
38 Angiotensin-Converting Enzyme Inhibitors Phase 4
39 Rosuvastatin Calcium Phase 4 147098-20-2
40 Antitubercular Agents Phase 4
41 Antibiotics, Antitubercular Phase 4
42 Chloroquine diphosphate Phase 4 50-63-5
43 Antifungal Agents Phase 4
44 Hydroxycholecalciferols Phase 4
45 Ibandronic Acid Phase 4
46 Antimitotic Agents Phase 4
47 Sodium Channel Blockers Phase 4
48 Anticonvulsants Phase 4
49 Diuretics, Potassium Sparing Phase 4
50 Chlorhexidine gluconate Phase 4

Interventional clinical trials:

(show top 50) (show all 1060)
# Name Status NCT ID Phase Drugs
1 Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in SLE Patients With Corticosteroid Therapy and High LDL Cholesterol Level Unknown status NCT00866229 Phase 4 Rosuvastatin;Simvastatin
2 Endothelial Dysfunction in Systemic Lupus Erythematosus: Its Contribution to Abnormalities in Coronary Perfusion. Unknown status NCT00188188 Phase 4 quinipril
3 A Two-part Study Exploring the Efficacy, Safety, and Pharmacodynamics of Acthar in Systemic Lupus Erythematosus Patients With a History of Persistently Active Disease Unknown status NCT01753401 Phase 4 Acthar;Placebo for Acthar
4 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
5 Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy Unknown status NCT02270970 Phase 4
6 Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy:a Single Center Prospective Randomized Controlled Study Unknown status NCT02765594 Phase 4 Hydroxychloroquine Sulfate;Valsartan
7 A Multicenter, Randomised, Double-blind Placebo Controlled Trial on the Efficacy and Safety of add-on Metformin to Conventional Immunosuppressants in Systemic Lupus Erythematosus Completed NCT02741960 Phase 4 metformin;placebo
8 A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Acthar Gel in Subjects With Persistently Active Systemic Lupus Erythematosus Despite Moderate Dose Corticosteroids Completed NCT02953821 Phase 4 Acthar Gel;Placebo Gel
9 Low Dose Aspirin and Statins for Primary Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus: A Randomized Double-blind Placebo-controlled Trial Completed NCT00371501 Phase 4 Rosuvastatin;placebo;aspirin;placebo
10 A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race With Systemic Lupus Erythematosus (SLE) Completed NCT01632241 Phase 4 Standard therapy
11 A Prospective, Randomised, Double-blind, Placebo-controlled Trial Evaluating the Effects of Mycophenolate Mofetil on 'Surrogate Markers' for Atherosclerosis in Female Patients With SLE. Completed NCT01101802 Phase 4 Mycophenolate mofetil;sugar pill
12 Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis Completed NCT00125307 Phase 4 tacrolimus
13 A Phase 4, Multi-Center, Randomized, Open-Label Study to Evaluate the Effect of BENLYSTA™ (Belimumab; HGS1006) on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE) Completed NCT01597492 Phase 4
14 Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus, a Randomized, Double-blind, Placebo-controlled Clinical Trial Completed NCT01322308 Phase 4 pioglitazone;placebo
15 Study of the Reduction of Systemic Lupus Erythematosus Flares Through Adaptation of the Dosage of Hydroxychloroquine to Its Whole-blood Concentration. National Multicenter Randomized Prospective Study Completed NCT00413361 Phase 4 versus hydroxychloroquine
16 A Single-site, Investigator Initiated Open-Label Trial of H.P. Acthar Gel (Repository Corticotropin Injection)an Adrenocorticotropic Hormone (ACTH) Analogue in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus (SLE) Completed NCT01769937 Phase 4 H.P. Acthar Gel
17 Lupus Atherosclerosis Prevention Study Completed NCT00120887 Phase 4 Atorvastatin
18 A Randomized, Double-blind, Placebo-controlled, Clinical Trial of Omega-3-polyunsaturated Fatty Acids in Subjects With SLE. Completed NCT00828178 Phase 4 Omega-3
19 Effect Of Hormone Replacement Therapy On Disease Activity, Menopausal Symptoms And Bone Mineral Density In Peri/Postmenopausal Women With Systemic Lupus Erythematosus.Randomized Clinical Trial Completed NCT00392093 Phase 4 Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d
20 Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With Systemic Lupus Erythematosus (SLE): a Controlled Study Completed NCT00911521 Phase 4 human papillomavirus vaccination (Gardasil)
21 Immunogenicity and Safety of a Herpes Zoster Vaccine (Zostavax) in Patients With Systemic Lupus Erythematosus: a Randomized Controlled Trial Completed NCT02477150 Phase 4
22 Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus-Prevalence,Risk Factors and Treatment Completed NCT00668330 Phase 4 Ibandronate+alfacalcidol+calcium;placebo ibandronate+alfacalcidol+calcium
23 Randomized Controlled Trial to Evaluate the Efficacy of Enteric-coated Mycophenolate Sodium Versus Azathioprine for the Induction and Maintenance of Remission of the Extra-renal Lupus Manifestations Completed NCT01112215 Phase 4 Azathioprine;Enteric-Coated Mycophenolate Sodium
24 Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis Completed NCT01206569 Phase 4 Long-acting tacrolimus (Advagraf, Astellas Pharma)
25 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
26 Evaluation of Vaccination Against Influenza (Seasonal and H1N1) in Patients Presenting Systemic or Autoimmune Diseases Treated or Not With Steroids, and/or Immunosuppressant, and/or Biotherapy: an Open, Prospective Trial (MAIVAX) Completed NCT01065285 Phase 4
27 Immunogenicity and Safety of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases Completed NCT03540823 Phase 4
28 Comparison of Intravenous Low Dose Versus High Dose Cyclophosphamide as Induction Therapy in the Treatment of Proliferative Lupus Nephritis Completed NCT02645565 Phase 4 Cyclophosphamide;Azathioprine;Methylprednisolone
29 Renal Division, Peking University First Hospital, Institute of Nephrology, Peking University, Key Laboratory of Renal Disease Completed NCT02351752 Phase 4 Hydroxychloroquine Sulfate
30 Efficacy of Lower Dose Prednisolone in the Induction of Remission of Lupus Nephritis Completed NCT04146220 Phase 4 Prednisolone
31 Possible Role of Chloroquine in Conjunction to Prednisone to Induce a Complete Remission in the Treatment of Autoimmune Hepatitis: a Randomized Trial Completed NCT02463331 Phase 4 Chloroquine diphosphate;prednisone;azathioprine
32 Estimation of Interleukin-21 Levels in Gingival Crevicular Fluid in Patients With Periodontal Health and Disease Following Non-surgical Periodontal Therapy: A Clinico-biochemical Study Completed NCT02861937 Phase 4
34 Phenytoin as an Augmentation for SSRI Failures: A Controlled Study Completed NCT00146237 Phase 4 phenytoin
35 Open Label Study of Hydroxychloroquine for Alopecia Areata, Alopecia Totalis Completed NCT00176982 Phase 4 Hydroxychloroquine
36 Effects of Atorvastatin on Disease Activity and HDL Cholesterol Anti-inflammatory Properties in Patients With Rheumatoid Arthritis Completed NCT00356473 Phase 4 Atorvastatin
37 Management of Pain in Oral Lichen Planus Patients: A Comparative Pilot Study Completed NCT03572959 Phase 4 0.1 % topical triamcinolone acetonide
38 Low-dose Combination of Mycophenolate Mofetil and Tacrolimus for Refractory Lupus Nephritis: a 12-month Prospective Study Completed NCT01203709 Phase 4 low dose combination of MMF and Tac
39 To Compare the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis Completed NCT00371319 Phase 4 tacrolimus;mycophenolate mofetil
40 Phase II Study To Evaluate The Safety And Efficacy Of Lenalidomide For The Treatment Of Refractory Cutaneous Lupus Completed NCT01408199 Phase 4 Lenalidomide
41 Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX® Completed NCT02437786 Phase 4 GRAZAX
42 Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon Completed NCT00048776 Phase 4 Pletal
43 Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia Completed NCT03229746 Phase 4 Hydroxychloroquine;vincristine;azathioprine
44 Steroid-induced Mood Changes in Patients With Inflammatory Bowel Disease Completed NCT01981889 Phase 4 Prednisone
45 A Multicenter, Randomized, Prospective, Open-Label Trial of Rituximab in the Treatment of Progressive IgA Nephropathy Completed NCT00498368 Phase 4 Intravenous Rituximab;ACE/ARB
46 Everolimus in Association With Very Low-dose Tacrolimus Versus Enteric-coated Mycophenolate Sodium With Low-dose Tacrolimus in de Novo Renal Transplant Recipients - A Prospective Single Center Study Completed NCT02084446 Phase 4 Everolimus;Very Low Tacrolimus;Low Tacrolimus;Steroids;Thymoglobulin;Sodium Mycophenolate
47 A Phase IV, Open Label Study to Evaluate the Safety and Efficacy of Intramuscular (IM) Alefacept (Amevive) 15mg/wk in Subjects 18 Years and Older With Moderate to Severe Atopic Dermatitis Completed NCT00832585 Phase 4 Alefacept
48 A Prospective, Randomized, Open Label, Case-Controlled Study on the Efficacy of Mycophenolate Mofetil for IgA Nephropathy Patients With Heavy Proteinuria Despite Angiotensin Blockade Completed NCT00863252 Phase 4 mycophenolate mofetil;angiotensin blockade
49 Single-dose Linaclotide for Capsule Endoscopy Preparation Completed NCT02465385 Phase 4 Linaclotide
50 Pilot Open-Label Clinical Trial to Test Efficacy and Safety of Combination of Clobex® Spray With Excimer Laser Therapy [Photomedex XTRAC ® Velocity] in the Treatment of Generalized Plaque Psoriasis Followed by Maintenance With Topical Vectical® Ointment Completed NCT01012713 Phase 4 Clobex Spray;Vectical Ointment

Search NIH Clinical Center for Lupus Erythematosus

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Chloroquine hydrochloride
chloroquine phosphate
Hydroxychloroquine Sulfate
Triamcinolone Acetonide
triamcinolone diacetate
triamcinolone hexacetonide

Genetic Tests for Lupus Erythematosus

Anatomical Context for Lupus Erythematosus

MalaCards organs/tissues related to Lupus Erythematosus:

T Cells, B Cells, Skin, Testes, Heart, Kidney, Bone

Publications for Lupus Erythematosus

Articles related to Lupus Erythematosus:

(show top 50) (show all 39369)
# Title Authors PMID Year
Vaccination, atherosclerosis and systemic lupus erythematosus. 54 61
19880570 2009
[Association of interleukin-18 gene polymorphism with genetic susceptibility to systematic lupus erythematosus in Guangxi Zhuang population]. 54 61
18683145 2008
Clinical manifestations and vascular events in patients with lupus erythematosus anticardiolipin antibodies and raynaud's phenomenon. 54 61
17550096 2006
Vasculopathy and renal injury in lupus erythematosus: does shedding of the endothelial protein C receptor play a role? 54 61
15954934 2005
Sudden sensorineural hearing loss in lupus erythematosus associated with antiphospholipid syndrome: case report and review. 54 61
15825571 2005
The concomitant presence of lupus anticoagulant, anticardiolipin and anti-beta2-glycoprotein i antibodies could be associated with acquired activated protein c resistance in non-systemic lupus erythematosus patients. 54 61
12716380 2003
Catalytic heterogenity of polyclonal RNA-hydrolyzing IgM from sera of patients with lupus erythematosus. 54 61
11208354 2000
Polymorphisms of the xenobiotic-metabolizing enzymes CYP1A1 and NAT-2 in systemic sclerosis and lupus erythematosus. 54 61
10599336 1999
Mucocutaneous disease in Arabs with systemic lupus erythematosus: clinical expression and relevance to autoantibodies. 54 61
9863895 1998
Autoantibody response to the Ro/La particle may predict outcome in neonatal lupus erythematosus. 54 61
7774062 1995
Renal transplantation in anticardiolipin antibody-positive lupus erythematosus patients. 54 61
8311089 1994
Prevalence of anticardiolipin antibodies in subacute cutaneous lupus erythematosus. 54 61
1301991 1992
[Anticardiolipin antibodies in cutaneous lupus erythematosus. Incidence and importance as a marker of vascular symptoms]. 54 61
1577600 1992
Neonatal lupus erythematosus syndrome: analysis of C4 allotypes and C4 genes in 18 families. 54 61
1545698 1992
Neuropsychiatric lupus erythematosus, cerebral infarctions, and anticardiolipin antibodies. 54 61
2317112 1990
Systemic lupus erythematosus and menopause. 61
31657240 2020
Anti-tumor necrosis factor (TNF)-induced lupus in a patient with hidradenitis suppurativa. 61
31633193 2020
All-cause hospitalizations and mortality in systemic lupus erythematosus in the US: results from a national inpatient database. 61
31773392 2020
Tobacco smoking is an independent factor associated with retinal damage in systemic lupus erythematosus: a cross-sectional and retrospective study. 61
31773393 2020
Longitudinal anti-nuclear antibody (ANA) seroconversion in systemic lupus erythematosus: a prospective study of Swedish cases with recent-onset disease. 61
31778219 2020
Advances in the diagnosis, pathogenesis and treatment of neuropsychiatric systemic lupus erythematosus. 61
31895125 2020
Notch notches lupus. 61
31980071 2020
Factors associated with long-term cardiac dysfunction in neonatal lupus. 61
31672776 2020
Two Unusual Cases of Discoid Lupus Erythematosus Associated With Xanthomatized Macrophages. 61
31464721 2020
Association between oral lesions and disease activity in lupus erythematosus. 61
31566809 2020
Management of cutaneous manifestations of lupus erythematosus: A systematic review. 61
31526594 2020
Basal cell carcinoma arising over lesion of discoid lupus erythematosus: a rare occurrence. 61
31847697 2020
Magnesium-dependent activated partial thromboplastin time assay-Simple method for lupus anticoagulant detection. 61
31821738 2020
DNA methylation changes on immune cells in Systemic Lupus Erythematosus. 61
32019373 2020
Epilepsy in systemic lupus erythematosus: prevalence and risk factors. 61
31454130 2020
Hormonal Dependence and Cancer in Systemic Lupus Erythematosus. 61
31529686 2020
IRAK2 is associated with systemic lupus erythematosus risk. 61
31650390 2020
PTPN22 Gene Polymorphisms in Pediatric Systemic Lupus Erythematosus. 61
31232672 2020
Sex Differences in Systemic Lupus Erythematosus: Epidemiology, Clinical Considerations, and Disease Pathogenesis. 61
32029091 2020
Th1, Th2, and Th17 cytokines in systemic lupus erythematosus. 61
31771364 2020
The YB-1:Notch-3 axis modulates immune cell responses and organ damage in systemic lupus erythematosus. 61
31882173 2020
[Coexistence of sickle cell disease and systemic lupus erythematosus]. 61
32030937 2020
Treat-to-target in systemic lupus erythematosus: Where are we? 61
32014364 2020
Elevated Blood and Urinary ICAM-1 is a Biomarker for Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis. 61
31298049 2020
Bioinformatics identification of key candidate genes and pathways associated with systemic lupus erythematosus. 61
31673979 2020
Time to Lupus Low Disease Activity State in the Hopkins Lupus Cohort: Role of African American Ethnicity. 61
31507071 2020
Rapid induction of clinical remission by immunoadsorption for refractory lupus retinopathy complicated with life-threatening neuropsychiatric lupus. 61
31615755 2020
Determination of serum free light chains as a marker of systemic lupus flare. 61
31773496 2020
Retraction Note: Microglia-dependent synapse loss in type I interferon-mediated lupus. 61
32025017 2020
First report of a pseudorabies-virus-infected wolf (Canis lupus) in China. 61
31863263 2020
Choroidal thickness in lupus nephritis. 61
31924146 2020
Cryptococcal meningitis in patients with lupus nephritis. 61
31838635 2020
Role of A20/TNFAIP3 deficiency in lupus nephritis in MRL/lpr mice. 61
31811410 2020
Efficacy of mesenchymal stem cells in animal models of lupus nephritis: a meta-analysis. 61
32019582 2020
Accelerating Medicines Partnership: Organizational Structure and Preliminary Data From the Phase 1 Studies of Lupus Nephritis. 61
31502417 2020

Variations for Lupus Erythematosus

Expression for Lupus Erythematosus

Search GEO for disease gene expression data for Lupus Erythematosus.

Pathways for Lupus Erythematosus

Pathways related to Lupus Erythematosus according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
11.93 C4B C4A C1QC C1QB C1QA
6 11.9 CR2 C4B C4A C1QC C1QB C1QA
Show member pathways
11.76 CR2 C4B C4A C1QC C1QB C1QA
8 11.6 C4B C4A C1QC C1QB C1QA
Show member pathways
11.46 CR2 C4B C4A C1QC C1QB C1QA
10 11.15 C1QC C1QB C1QA
11 11.15 FCGR3A FCGR2B C4B C4A C1QC C1QB

GO Terms for Lupus Erythematosus

Cellular components related to Lupus Erythematosus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 postsynapse GO:0098794 9.43 C1QC C1QB C1QA
2 collagen trimer GO:0005581 9.33 C1QC C1QB C1QA
3 blood microparticle GO:0072562 9.26 C4B C4A C1QC C1QB
4 complement component C1 complex GO:0005602 8.62 C1QB C1QA

Biological processes related to Lupus Erythematosus according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.95 FCGR3A FCGR2B CTLA4 CR2 C1QC
2 immune system process GO:0002376 9.81 TLR5 PTPN22 PDCD1 IRF5 CTLA4 CR2
3 complement activation, classical pathway GO:0006958 9.73 CR2 C4B C4A C1QC C1QB C1QA
4 complement activation GO:0006956 9.72 C4B C4A C1QC C1QB C1QA
5 regulation of innate immune response GO:0045088 9.58 PTPN22 FCGR2B
6 negative regulation of interleukin-6 secretion GO:1900165 9.58 PTPN22 BANK1
7 negative regulation of immune response GO:0050777 9.58 PDCD1 FCGR2B CTLA4
8 negative regulation of B cell proliferation GO:0030889 9.57 FCGR2B CTLA4
9 histone mRNA metabolic process GO:0008334 9.56 SSB SNRPB
10 DNA catabolic process, endonucleolytic GO:0000737 9.54 DNASE1L3 DNASE1
11 synapse pruning GO:0098883 9.54 C1QC C1QB C1QA
12 negative regulation of B cell activation GO:0050869 9.52 FCGR2B BANK1
13 DNA catabolic process GO:0006308 9.51 DNASE1L3 DNASE1
14 positive regulation of apoptotic cell clearance GO:2000427 9.49 C4B C4A
15 neutrophil activation involved in immune response GO:0002283 9.48 DNASE1L3 DNASE1
16 regulation of acute inflammatory response GO:0002673 9.46 DNASE1L3 DNASE1
17 regulation of neutrophil mediated cytotoxicity GO:0070948 9.43 DNASE1L3 DNASE1
18 regulation of complement activation GO:0030449 9.43 CR2 C4B C4A C1QC C1QB C1QA
19 innate immune response GO:0045087 9.28 TRIM21 TLR5 IRF5 CR2 C4B C4A

Molecular functions related to Lupus Erythematosus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.25 TRIM21 TLR5 STAT4 SSB SNRPB PTPN22
2 IgG binding GO:0019864 9.26 FCGR3A FCGR2B
3 deoxyribonuclease activity GO:0004536 9.16 DNASE1L3 DNASE1
4 complement binding GO:0001848 8.96 CR2 C4B
5 deoxyribonuclease I activity GO:0004530 8.62 DNASE1L3 DNASE1

Sources for Lupus Erythematosus

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....